Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept plus standard therapy for active neuropsychiatric lupus
ChiCTR2200062250Phase 4Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Jul 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of telitacicept in systemic lupus erythematosus (SLE) and neuropsychiatric systemic lupus erythematosus (NPSLE) (2 arms), sponsored by First Hospital of China Medical University. Primary endpoint: BILAG neurological score. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
telitacicept
03
Conditions
systemic lupus erythematosus (SLE)neuropsychiatric systemic lupus erythematosus (NPSLE)
Beyond the preview
Go deeper on ChiCTR2200062250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062250.